Full Text View
Tabular View
No Study Results Posted
Related Studies
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
This study has been terminated.
( Lack of efficacy/Manufacturer stopping drug development )
Study NCT00511043   Information provided by Duke University
First Received: August 1, 2007   Last Updated: November 6, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Large-Cell, Diffuse
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
PTK787/ZK 222584
Additional drug interventions recognized in this trial
Vatalanib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
Duke University
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services